Loading...
XHKG
2877
Market cap770mUSD
Jun 13, Last price  
7.97HKD
1D
2.69%
1Q
-9.70%
Jan 2017
-8.98%
IPO
70.43%
Name

China Shineway Pharmaceutical Group Ltd

Chart & Performance

D1W1MN
P/E
6.56
P/S
1.46
EPS
1.11
Div Yield, %
7.25%
Shrs. gr., 5y
-0.66%
Rev. gr., 5y
6.90%
Revenues
3.78b
-16.35%
831,379,000841,475,0001,012,885,0001,275,179,0001,633,223,0002,038,379,0001,984,542,0002,132,249,0002,187,115,0002,229,201,0002,054,809,0001,993,379,0001,919,608,0002,570,196,0002,705,996,0002,655,701,0003,223,550,0003,950,636,0004,516,538,0003,778,043,000
Net income
840m
-13.35%
337,006,000332,977,000490,641,000398,242,000767,304,000821,756,000755,600,000647,704,000683,647,000704,775,000657,906,000589,196,000451,553,000505,876,000503,150,000295,033,000556,674,000722,773,000969,510,000840,052,000
CFO
0k
-100.00%
457,646,000417,409,000401,970,000405,280,0001,057,320,000579,425,000485,062,000635,673,000519,885,999773,158,000744,707,000733,526,000490,646,000532,586,000367,996,000638,566,000703,150,0001,109,676,000932,635,0000
Dividend
Sep 10, 20240.12 HKD/sh
Earnings
Aug 27, 2025

Profile

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.
URL
http://www.shineway.com.hk
IPO date
Dec 02, 2004
Employees
4,131
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,778,043
-16.35%
4,516,538
14.32%
3,950,636
22.56%
Cost of revenue
2,935,441
3,541,003
3,228,232
Unusual Expense (Income)
NOPBT
842,602
975,535
722,404
NOPBT Margin
22.30%
21.60%
18.29%
Operating Taxes
305,669
270,743
194,252
Tax Rate
36.28%
27.75%
26.89%
NOPAT
536,933
704,792
528,152
Net income
840,052
-13.35%
969,510
34.14%
722,773
29.84%
Dividends
(317,268)
(241,728)
Dividend yield
5.75%
4.22%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
338,271
300,971
6,530
Long-term debt
24,783
1,681
8,354
Deferred revenue
88,888
163,986
Other long-term liabilities
116,374
Net debt
(6,127,119)
(5,606,124)
(6,446,324)
Cash flow
Cash from operating activities
932,635
1,109,676
CAPEX
(144,325)
(129,463)
Cash from investing activities
(49,540)
(45,420)
Cash from financing activities
(26,738)
(250,038)
FCF
778,194
554,444
868,119
Balance
Cash
6,490,173
5,908,776
5,050,188
Long term investments
1,411,020
Excess cash
6,301,271
5,682,949
6,263,676
Stockholders' equity
7,466,904
6,413,944
6,455,277
Invested Capital
1,628,534
1,742,033
182,484
ROIC
31.86%
73.24%
152.51%
ROCE
10.63%
13.11%
11.17%
EV
Common stock shares outstanding
755,400
755,400
755,400
Price
9.65
32.01%
7.31
-3.69%
7.59
10.16%
Market cap
7,289,610
32.01%
5,521,974
-3.69%
5,733,486
10.20%
EV
1,162,491
(84,150)
(217,947)
EBITDA
842,602
1,152,637
908,266
EV/EBITDA
1.38
Interest
2,737
630
Interest/NOPBT
0.28%
0.09%